Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 19/20 | 0.55 |
| ▸ | CBLC | Q9ULV8 | 2/20 | 0.55 |
| ▸ | CBL | P22681 | 13/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31486110 | 0.94 | CBLB (0.53) | CBLBCBLCCBL | |
| SCHEMBL34468182 | 0.93 | CBLB (0.52) | CBLBCBLCCBL | |
| SCHEMBL31485875 | 0.90 | CBLB (0.56) | CBLBCBLCCBL | |
| SCHEMBL30838257 | 0.88 | CBLB (0.56) | CBLBCBLCCBL | |
| SCHEMBL31485957 | 0.88 | CBLB (0.53) | CBLBCBLCCBL | |
| SCHEMBL31485889 | 0.86 | CBLB (0.48) | CBLBCBLCCBL | |
| SCHEMBL31578167 | 0.85 | CBLB (0.74) | CBLBCBLCCBL | |
| SCHEMBL30521015 | 0.85 | CBLB (0.59) | CBLBCBLCCBL | |
| SCHEMBL25348967 | 0.85 | CBLB (0.55) | CBLBCBLCCBL | |
| SCHEMBL30521443 | 0.85 | CBLB (0.55) | CBLBCBLCCBL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025076299-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBLC, CBL | CBLB 1/4885CBLC 2/4885CBL 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.